Harnessing oncolytic virus-mediated immunity
Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-onco...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Online |
| 言語: | 英語 |
| 出版事項: |
Frontiers Media SA
2021
|
| 主題: | |
| オンライン･アクセス: | 18596 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
| _version_ | 1869517381310611456 |
|---|---|
| author | Volker Schirrmacher Philippe Fournier |
| author_browse | Philippe Fournier Volker Schirrmacher |
| author_facet | Volker Schirrmacher Philippe Fournier |
| author_sort | Volker Schirrmacher |
| collection | Directory of Open Access Books |
| description | Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity. |
| format | Online |
| id | doab-20.500.12854ir-49124 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-491242024-03-30T23:22:05Z Harnessing oncolytic virus-mediated immunity Volker Schirrmacher Philippe Fournier R5-920 RC581-607 RC254-282 anti-tumor activity immunovirotherapy oncolytic virus oncolytic virotherapy tumor-associated antigen immunotherapeutic approaches anti-viral response thema EDItEUR::M Medicine and Nursing Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity. 2021-02-11T15:08:10Z 2021-02-11T15:08:10Z 2016-02-05 17:24:33 2015 book 18596 16648714 9782889194506 https://directory.doabooks.org/handle/20.500.12854/49124 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Harnessing_Oncolytic_Virus-mediated_Antitumor_Immunity/448#nogo http://journal.frontiersin.org/researchtopic/1613/harnessing-oncolytic-virus-mediated-antitumor-immunity Frontiers Media SA 10.3389/978-2-88919-450-6 10.3389/978-2-88919-450-6 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889194506 110 open access |
| spellingShingle | R5-920 RC581-607 RC254-282 anti-tumor activity immunovirotherapy oncolytic virus oncolytic virotherapy tumor-associated antigen immunotherapeutic approaches anti-viral response thema EDItEUR::M Medicine and Nursing Volker Schirrmacher Philippe Fournier Harnessing oncolytic virus-mediated immunity |
| title | Harnessing oncolytic virus-mediated immunity |
| title_full | Harnessing oncolytic virus-mediated immunity |
| title_fullStr | Harnessing oncolytic virus-mediated immunity |
| title_full_unstemmed | Harnessing oncolytic virus-mediated immunity |
| title_short | Harnessing oncolytic virus-mediated immunity |
| title_sort | harnessing oncolytic virus mediated immunity |
| topic | R5-920 RC581-607 RC254-282 anti-tumor activity immunovirotherapy oncolytic virus oncolytic virotherapy tumor-associated antigen immunotherapeutic approaches anti-viral response thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC581-607 RC254-282 anti-tumor activity immunovirotherapy oncolytic virus oncolytic virotherapy tumor-associated antigen immunotherapeutic approaches anti-viral response thema EDItEUR::M Medicine and Nursing |
| url | 18596 |
| work_keys_str_mv | AT volkerschirrmacher harnessingoncolyticvirusmediatedimmunity AT philippefournier harnessingoncolyticvirusmediatedimmunity |